Foundation Resource Management Cut Its Encana (ECA) Holding; Sucampo Pharmaceuticals (SCMP) Sentiment Is 0.89

April 7, 2018 - By Annabelle Johnson

Encana Corporation (NYSE:ECA) Logo

Foundation Resource Management Inc decreased Encana (ECA) stake by 39.48% reported in 2017Q4 SEC filing. Foundation Resource Management Inc sold 521,910 shares as Encana (ECA)’s stock declined 11.75%. The Foundation Resource Management Inc holds 800,015 shares with $10.66 million value, down from 1.32M last quarter. Encana now has $10.33B valuation. The stock decreased 1.80% or $0.2 during the last trading session, reaching $10.92. About 5.99M shares traded. Encana Corporation (NYSE:ECA) has risen 5.00% since April 7, 2017 and is uptrending. It has underperformed by 6.55% the S&P500.

Sucampo Pharmaceuticals Inc (SCMP) investors sentiment decreased to 0.89 in 2017 Q4. It’s down -0.76, from 1.65 in 2017Q3. The ratio has worsened, as 82 funds started new or increased stock positions, while 92 sold and reduced equity positions in Sucampo Pharmaceuticals Inc. The funds in our database now own: 32.72 million shares, up from 29.83 million shares in 2017Q3. Also, the number of funds holding Sucampo Pharmaceuticals Inc in top ten stock positions increased from 1 to 2 for an increase of 1. Sold All: 40 Reduced: 52 Increased: 41 New Position: 41.

Since January 1, 0001, it had 0 insider buys, and 1 sale for $825,000 activity.

It closed at $18 lastly. It is down 0.00% since April 7, 2017 and is . It has underperformed by 11.55% the S&P500.

Ratings analysis reveals 67% of Sucampo Pharma’s analysts are positive. Out of 3 Wall Street analysts rating Sucampo Pharma, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $16.0 while the high is $19.0. The stock’s average target of $17.50 is -2.78% below today’s ($18) share price. SCMP was included in 3 notes of analysts from September 7, 2016. Mizuho maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Monday, November 14. Mizuho has “Neutral” rating and $16.0 target. The rating was maintained by Maxim Group with “Buy” on Tuesday, November 15. The company was initiated on Wednesday, September 7 by Northland Capital.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company has market cap of $847.54 million. The companyÂ’s marketed product includes AMITIZA , a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. It currently has negative earnings. The Company’s product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

Krensavage Asset Management Llc holds 7.3% of its portfolio in Sucampo Pharmaceuticals, Inc. for 1.30 million shares. Havens Advisors Llc owns 100,000 shares or 1.35% of their US portfolio. Moreover, Piermont Capital Management Inc. has 1.02% invested in the company for 172,980 shares. The New York-based Prelude Capital Management Llc has invested 0.97% in the stock. Alpine Associates Management Inc., a New Jersey-based fund reported 1.50 million shares.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Chart